© 2000 American Heart Association, Inc.
Vascular Biology |
Assay for Human Matrix Gla Protein in Serum
Potential Applications in the Cardiovascular Field
From the Department of Biochemistry and Cardiovascular Research Institute (L.A.J.L.M.B., P.D., B.L.M.G.G., H.M.H.S., B.A.M.S., C.V.), University of Maastricht; the Department of Molecular Cell Biology (W.D.), University of Maastricht; and the Department of Hematology (K.H.), University Hospital, Maastricht, the Netherlands.
Correspondence to Dr C. Vermeer, Department of Biochemistry, University of Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail c.vermeer{at}bioch.unimaas.nl
Abstract—Matrix Gla protein (MGP) is synthesized in a vitamin K–dependent way in smooth muscle cells of the healthy vessel wall, and its mRNA transcription is substantially upregulated in atherosclerotic lesions. Here we report the preparation of a monoclonal antibody against human MGP and its use in an enzyme-linked immunosorbent assay. The intra-assay and interassay coefficients of variation in serum samples were 5.4% and 12.6%, respectively, and the lower detection limit was 8.5% of the normal serum value. Individual within-day variations were <11% and did not show a distinct circadian pattern. Day-to-day variations in fasting morning samples were <8%. In a first explorative survey, serum MGP concentrations were found to be significantly increased in patients with severe atherosclerosis, whereas these values were normal in those with low bone mass and osteoporosis. This finding is consistent with the high MGP mRNA expression observed in atherosclerotic vessels and plaques. More elaborate studies are required to assess the potential clinical utility of this newly developed assay.
Key Words: vitamin K • 
-carboxyglutamate • atherosclerosis • ectopic calcification • diagnostics
This article has been cited by other articles:
 |
|
 |
|
  C. J. O'Donnell, M. K. Shea, P. A. Price, D. R. Gagnon, P. W. F. Wilson, M. G. Larson, D. P. Kiel, U. Hoffmann, M. Ferencik, M. E. Clouse, et al. Matrix Gla Protein Is Associated With Risk Factors for Atherosclerosis but not With Coronary Artery Calcification Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2769 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Adams and J. Pepping Vitamin K in the treatment and prevention of osteoporosis and arterial calcification Am. J. Health Syst. Pharm., August 1, 2005; 62(15): 1574 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schurgers, K. J.F. Teunissen, M. H.J. Knapen, M. Kwaijtaal, R. van Diest, A. Appels, C. P. Reutelingsperger, J. P.M. Cleutjens, and C. Vermeer Novel Conformation-Specific Antibodies Against Matrix {gamma}-Carboxyglutamic Acid (Gla) Protein: Undercarboxylated Matrix Gla Protein as Marker for Vascular Calcification Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1629 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bern Observations on Possible Effects of Daily Vitamin K Replacement, Especially Upon Warfarin Therapy JPEN J Parenter Enteral Nutr, November 1, 2004; 28(6): 388 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Reynolds, A. J. Joannides, J. N. Skepper, R. McNair, L. J. Schurgers, D. Proudfoot, W. Jahnen-Dechent, P. L. Weissberg, and C. M. Shanahan Human Vascular Smooth Muscle Cells Undergo Vesicle-Mediated Calcification in Response to Changes in Extracellular Calcium and Phosphate Concentrations: A Potential Mechanism for Accelerated Vascular Calcification in ESRD J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2857 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Schurgers, M. J. Shearer, B. A. M. Soute, I. Elmadfa, J. Harvey, K.-H. Wagner, R. Tomasch, and C. Vermeer Novel effects of diets enriched with corn oil or with an olive oil/sunflower oil mixture on vitamin K metabolism and vitamin K-dependent proteins in young men J. Lipid Res., June 1, 2002; 43(6): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Dhore, J. P.M. Cleutjens, E. Lutgens, K. B.J.M. Cleutjens, P. P.M. Geusens, P. J.E.H.M. Kitslaar, J. H.M. Tordoir, H. M.H. Spronk, C. Vermeer, and M. J.A.P. Daemen Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1998 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Engelse, J. M Neele, A. L.J.J Bronckers, H. Pannekoek, and C. J.M de Vries Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor {alpha}-1 and the protective factor matrix gla protein in human atherogenesis Cardiovasc Res, November 1, 2001; 52(2): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Hackeng, J. Rosing, H. M.H. Spronk, and C. Vermeer Total chemical synthesis of human matrix Gla protein Protein Sci., April 1, 2001; 10(4): 864 - 870. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Farzaneh-Far, J. D. Davies, L. A. Braam, H. M. Spronk, D. Proudfoot, S.-W. Chan, K. M. O'Shaughnessy, P. L. Weissberg, C. Vermeer, and C. M. Shanahan A Polymorphism of the Human Matrix gamma -Carboxyglutamic Acid Protein Promoter Alters Binding of an Activating Protein-1 Complex and Is Associated with Altered Transcription and Serum Levels J. Biol. Chem., August 24, 2001; 276(35): 32466 - 32473. [Abstract] [Full Text] [PDF]
|
|